Amplified delivery of indium-111 to EGFR-positive human breast cancer cells.

Amplified delivery of indium-111 to EGFR-positive human breast cancer cells.

A method is described to amplify the delivery of 111In to human breast cancer cells utilizing a novel human serum albumin-human EGF (HSA-hEGF) bioconjugate substituted preferentially in the HSA domain with multiple DTPA metal chelators for 111In. 111In-DTPA-HSA-hEGF exhibited a lower receptor-bindin...

Descripció completa

Dades bibliogràfiques
Autors principals:	Wang, J, Chen, P, Su, Z, Vallis, K, Sandhu, J, Cameron, R, Hendler, A, Reilly, R
Format:	Journal article
Idioma:	English
Publicat:	2001

Ítems similars

Comparative antiproliferative effects of (111)In-DTPA-hEGF, chemotherapeutic agents and gamma-radiation on EGFR-positive breast cancer cells.
per: Chen, P, et al.
Publicat: (2002)

111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR.
per: Reilly, R, et al.
Publicat: (2000)

In-111-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR
per: Reilly, R, et al.
Publicat: (2000)

A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
per: Reilly, R, et al.
Publicat: (2000)

The anti-tumor effect of the auger electron-emitting radiopharmaceutical, In-111-hEGF against MDA-MB-468 human breast cancer xenografts is tumor-size dependent.
per: Chen, P, et al.
Publicat: (2001)

A phase I trial of In-111-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer
per: Vallis, K, et al.
Publicat: (2008)

A phase I clinical trial to evaluate the pharmacokinetics, toxicity and dosimetry of 111-indium-labeled human epidermal growth factor in patients with metastatic breast cancer
per: Vallis, K, et al.
Publicat: (2005)

Indium-111 labelling of liposomal HEGF for radionuclide delivery via ultrasound-induced cavitation
per: Owen, J, et al.
Publicat: (2019)

Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
per: Costantini, D, et al.
Publicat: (2010)

Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
per: Chen, P, et al.
Publicat: (2003)

(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
per: Costantini, D, et al.
Publicat: (2007)

Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF.
per: Hu, M, et al.
Publicat: (2007)

Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
per: Reilly, R, et al.
Publicat: (2006)

Preoperative Localization of a Gastrin-Secreting Tumour by Total Body Imaging with 111Indium-Labelled Pentatreotide
per: Humera Ali, et al.
Publicat: (1994-01-01)

A phase I study of Tc-99m-h-R3 monoclonal antibody (DiaCIM (R)), a humanized monoclonal antibody (mAB) for imaging EGFR-positive malignancies.
per: Reilly, R, et al.
Publicat: (2002)

Accumulation of 111In-Labelled EGF-Au-PEG Nanoparticles in EGFR-Positive Tumours is Enhanced by Co-administration of Targeting Ligand
per: Song, L, et al.
Publicat: (2017)

Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer.
per: Vallis, K, et al.
Publicat: (2014)

Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.
per: Costantini, D, et al.
Publicat: (2010)

Computational analysis of the number, area and density of gamma-H2AX foci in breast cancer cells exposed to (111)In-DTPA-hEGF or gamma-rays using Image-J software.
per: Cai, Z, et al.
Publicat: (2009)

Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF.
per: Cai, Z, et al.
Publicat: (2008)

Limitations of In-Vitro Labeling of Endothelial Cells with Indium-111 Oxine
per: H.M.H. Carr, et al.
Publicat: (1995-05-01)

Targeted Delivery of 111In Into the Nuclei of EGFR Overexpressing Cells via Modular Nanotransporters With Anti-EGFR Affibody
per: Tatiana S. Karyagina, et al.
Publicat: (2020-03-01)

Production and Quality Control of Indium-111 Pentetreotide Radiopharmaceutical in Iran
per: S. Y Fazaeli Hoseini Nezhad, et al.
Publicat: (2017-08-01)

111In-labelled polymeric nanoparticles incorporating a ruthenium-based radiosensitizer for EGFR-targeted combination therapy in oesophageal cancer cells
per: Gill, M, et al.
Publicat: (2018)

EGF-coated gold nanoparticles provide an efficient nano-scale delivery system for the molecular radiotherapy of EGFR-positive cancer.
per: Song, L, et al.
Publicat: (2016)

Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.
per: Costantini, D, et al.
Publicat: (2008)

Indium-111 labeled leukocyte accumulation in extremity soft tissue sarcoma
per: Victor Fong, MD, et al.
Publicat: (2017-06-01)

Reentrant Behavior of the Density vs. Temperature of Indium Islands on GaAs(111)A
per: Artur Tuktamyshev, et al.
Publicat: (2020-07-01)

Indium-111 radiolabelling of a brain-penetrant Aβ antibody for SPECT imaging
per: Tobias Gustavsson, et al.
Publicat: (2024-05-01)

Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
per: Bailey, K, et al.
Publicat: (2007)

Indium-111 labeled anti-CD33 monoclonal antibodies (mAbs) modified with nuclear-localizing sequences (NLS) kill mitoxantrone-resistant HL-60 acute myelogenous leukemia (AML) cells
per: Kersemans, V, et al.
Publicat: (2006)

A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
per: Reilly, R, et al.
Publicat: (2004)

Study of indium nitride and indium oxynitride band gaps
per: M. Sparvoli, et al.
Publicat: (2013-01-01)

Study of indium nitride and indium oxynitride band gaps
per: M. Sparvoli, et al.
Publicat: (2013-05-01)

111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1.
per: Cornelissen, B, et al.
Publicat: (2009)

The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study.
per: Justin Stebbing, et al.
Publicat: (2013-01-01)

Edwardsiella tarda Endocarditis Confirmed by Indium-111 White Blood Cell Scan: An Unusual Pathogen and Diagnostic Modality
per: Kayleigh M. Litton, et al.
Publicat: (2016-01-01)

Preliminary Study of a 1,5-Benzodiazepine-Derivative Labelled with Indium-111 for CCK-2 Receptor Targeting
per: Marco Verona, et al.
Publicat: (2021-02-01)

Utility of indium-111 platelet scintigraphy for understanding the mechanism of thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia
per: Pauline Durand, et al.
Publicat: (2023-05-01)

Ultrasound-mediated cavitation enhances the delivery of an EGFR-targeting liposomal formulation designed for chemo-radionuclide therapy
per: Thomas, E, et al.
Publicat: (2019)